Navigation Links
Genoa Pharmaceuticals announces $1.2M Financing
Date:11/8/2012

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Genoa Pharmaceuticals, a biotechnology company developing novel therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF), announced today the completion of a $1.2M financing. Funds from the financing will be used to advance its lead program, GP-101 (aerosol pirfenidone). IPF is a fatal lung disease caused by both genetic and environmental factors resulting in progressive lung scarring and characterized by reduced exercise capacity and chronic cough. IPF affects approximately 200,000 Americans and 135,000 Europeans.

Genoa was founded by Mark Surber, Ph.D., an aerosol development expert formerly with Mpex and Aires Pharmaceuticals. Dr. Surber serves as Genoa's President and Chief Scientific Officer. "IPF is a very serious disease with only 20% of patients surviving five years," said Dr. Surber. "Currently, there are no U.S. approved drugs, leaving lung transplant as the only option to extend life. Genoa's approach could be a significant advancement to treat patients with this devastating disease and we are excited about the opportunity to progress GP-101 into development."

Outside the United States, only oral pirfenidone is approved for the treatment of IPF. Sold by InterMune in Europe and Shionogi in Japan, this product has shown promise to extend life. However, the oral drug has been associated with gastrointestinal side effects that limit dosing and challenge patient compliance. To address this unmet need, Genoa has created GP-101 as a proprietary aerosol pirfenidone formulation for direct inhalation delivery to the lung. Compared to the oral medicine, inhaled GP-101 delivers an increased pirfenidone lung dose with improved pharmacokinetic parameters. As inhalation delivers more pirfenidone directly to the lung with reduced gastrointestinal exposure, inhaled GP-101 has the potential to improve the efficacy and safety profile of pirfenidone.

"We are pleased to have raised this initial seed financing," said Michael J. Kamdar, Genoa's Co-Founder and Chief Business Officer. "This financing will allow us to advance GP-101 to a key inflection point for prospective partners and investors by early 2013."

About Genoa Pharmaceuticals

Genoa Pharmaceuticals is committed to developing improved therapies for the treatment of Idiopathic Pulmonary Fibrosis. Based in San Diego, Genoa's lead program GP-101 (aerosol pirfenidone) is advancing towards the clinic for the treatment of IPF. Learn more at www.genoapharma.com


'/>"/>
SOURCE Genoa Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
2. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
3. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
4. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
5. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
6. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
7. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
8. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
10. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research ... Electrodes Market Analysis and Trends - Adhesion Type, Application, Usability - ... ... The Global Cardiology Electrodes Market is poised to grow at a ... prominent trends that the market is witnessing include advancements in extracellular ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):